New York Medicaid does not cover weight loss medication in NY when the drug is prescribed for weight loss itself. That exclusion applies to Wegovy, Ozempic, Mounjaro, Zepbound, Qsymia, and other GLP-1 receptor agonists whenever obesity or weight reduction is the reason for the prescription.1eMedNY. NYRx Pharmacy Benefits The same drugs can be covered when prescribed for a different qualifying condition, such as type 2 diabetes or cardiovascular disease, and children may have a separate path under federal law.
Why Weight Loss Drugs Are Excluded
Since April 2023, all outpatient prescription drugs for New York Medicaid enrollees have been handled through NYRx, the statewide pharmacy program. NYRx guidance states plainly that “weight loss has never been a Medicaid-approved reason for covering a drug,” and the exclusion also reaches drugs prescribed for weight gain and anorexia.1eMedNY. NYRx Pharmacy Benefits
The rule rests on two layers of law. Federal Medicaid law lets states exclude weight loss drugs from coverage.2KFF. Medicaid Coverage of and Spending on GLP-1s New York takes that option through 18 NYCRR ยง505.3(g)(3), which bars payment for “any drug which has weight reduction as its sole clinical use.”3Cornell Law Institute. 18 NYCRR 505.3 Because NYRx is the single statewide formulary, no Medicaid managed care plan in New York can independently choose to cover a weight loss prescription.4NY Department of Health. Pharmacy Transition FAQ
When the Same Drugs Are Covered
The exclusion turns on the reason for the prescription, not the drug itself. Ozempic and Mounjaro sit on the NYRx Preferred Drug List for type 2 diabetes, and a prescriber who documents diabetes as the diagnosis can generally get them covered without prior authorization, provided the patient’s claim history supports the covered use. Non-preferred agents in the class still require prior authorization.5FHSC. NYRx Drug Class Coverage Overview
Two more indications matter. Wegovy was approved by the FDA in March 2024 for reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. CMS guidance says state Medicaid programs must cover Wegovy for that cardiovascular use, though they can apply prior authorization and step therapy.6Managed Healthcare Executive. Medicaid, Medicare Part D to Provide Coverage of Wegovy, but Not for Weight Loss Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and coverage for that indication is likewise required.2KFF. Medicaid Coverage of and Spending on GLP-1s
The practical takeaway: if you have diabetes, established cardiovascular disease with obesity, or obstructive sleep apnea with obesity, the same medication that would be denied for weight loss alone may be covered for the qualifying condition. The diagnosis codes on the prescription matter, and the conversation to have is with your prescriber about which conditions your medical record supports.
Children Under 21 May Have More Options
Federal law gives Medicaid enrollees under age 21 broader coverage through the Early and Periodic Screening, Diagnostic and Treatment benefit. Under EPSDT, states must cover medically necessary treatments to correct or improve a child’s condition, even treatments considered optional for adults, and cannot apply blanket exclusions or hard caps.7NY Health Access. EPSDT – Early and Periodic Screening, Diagnostic and Treatment If a prescriber determines that an anti-obesity medication is medically necessary for a child or adolescent, EPSDT may require coverage on a case-by-case basis, regardless of the adult exclusion. Getting there usually takes detailed clinical documentation and often involves prior authorization or appeals.
Obesity Treatments Medicaid Does Cover
The prescription-drug exclusion does not mean obesity itself goes untreated. New York Medicaid covers bariatric surgery, including gastric bypass, gastric banding, and sleeve gastrectomy, subject to prior authorization for both managed care and fee-for-service members. Weight assessment and counseling on nutrition and physical activity are covered for members aged 3 to 17.8GWU STOP Obesity Alliance. Medicaid Obesity Coverage – New York The state will pay for weight loss surgery but not the medications that in some cases could be tried first.
Paying Out of Pocket
Manufacturer savings programs are generally not an option for Medicaid enrollees. Novo Nordisk’s NovoCare program offers Wegovy self-pay pricing starting at $149 per month for certain doses, but its eligibility terms exclude Medicaid beneficiaries.9NovoCare. Savings and Support Zepbound’s self-pay pricing through LillyDirect starts at $349 per month for the lowest dose.10Drugs.com. Zepbound Cost Without Insurance Those figures are the sticker price a Medicaid enrollee would face if paying cash.
What Could Change
Two bills in the New York Legislature would require Medicaid coverage of anti-obesity medications if enacted. Senate Bill S5798, sponsored by Senator Sepulveda, would add a section to the Social Services Law requiring Medicaid and managed care to cover FDA-approved chronic weight management drugs for adults with obesity who have at least one weight-related condition; it has a companion bill, A10820, and was referred to the Senate Health Committee in January 2026.11New York State Senate. Senate Bill S5798 Assembly Bill A2715, sponsored by Assemblymember Karines Reyes with more than a dozen co-sponsors, would require comprehensive Medicaid coverage for obesity treatment, including intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medications. It was introduced in January 2025 and re-referred to the Assembly Health Committee in January 2026.12New York State Senate. Assembly Bill A2715 Neither bill has advanced beyond committee.
At the federal level, a Biden-era CMS proposed rule would have required states to cover anti-obesity medications by treating obesity as a disease, but the Trump administration’s 2025 final rule dropped that mandate, while stating CMS “reserves the right to include provisions in future rulemaking.”13CMS. Contract Year 2026 Policy and Technical Changes – Final Rule In December 2025, CMS launched a different approach: the voluntary BALANCE model, in which CMS negotiates lower GLP-1 prices with manufacturers on behalf of participating state Medicaid programs. State Medicaid agencies became eligible to join starting in May 2026, with an application deadline of July 31, 2026, and the model covers Wegovy, Ozempic, Mounjaro, and Zepbound along with manufacturer-provided lifestyle support.14CMS. BALANCE State Medicaid Request for Applications Whether New York will participate has not been publicly confirmed,15KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and Governor Hochul’s FY 2027 executive budget included no proposals on Medicaid coverage of anti-obesity medications.16Office of the Governor. FY2027 Executive Budget
Until state law or federal rules change, the answer stays where it started. If weight loss is the reason on the prescription, New York Medicaid will not pay. If a covered condition is on your chart, ask your prescriber whether the medication you want can be prescribed for that condition instead.